Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
Status:
Not yet recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This is a phase IIb, randomized, double-blind, placebo-controlled, multicenter study to
evaluate the efficacy and safety of orelabrutinib in adult subjects with SLE who are
receiving standard of care (SOC) therapy.